A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Trial Details

NCT ID
NCT07629960
Phase
PHASE1 / PHASE2
Sponsor
Blueprint Medicines Corporation
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • BLU-924
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Pathologically confirmed diagnosis of metastatic Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant pancreatic ductal adenocarcinoma (PDAC), …
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
  • Patients must have received all standard therapies for their cancer type in the metastatic setting, unless they are unable to receive such therapie…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →